Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib

Fig. 4

Baseline genetic alterations affected the clinical response to Osimertinib. A Forest plot of hazard ratio (HR) and p value for ultivariate analyses of somatic mutations identified in more than 4 patients. B Forest plot of hazard ratio (HR) and p value for ultivariate analyses of SCNAs identified in more than 4 patients. C Comparison of PFS between PARP1 mutant-type patients and PARP1 wild-type patients. D Comparison of PFS between Patients with MYC amplification and MYC wild-type patients

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us